Cipla moves up on launching `Yurpeak`
Cipla is currently trading at Rs. 1498.40, up by 9.25 points or 0.62% from its previous closing of Rs. 1489.15 on the BSE.
The scrip opened at Rs. 1500.65 and has touched a high and low of Rs. 1500.65 and Rs. 1492.80 respectively. So far 2441 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1672.20 on 23-Oct-2025 and a 52 week low of Rs. 1310.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 1527.00 and Rs. 1485.00 respectively. The current market cap of the company is Rs. 120975.86 crore.
The promoters holding in the company stood at 29.21%, while Institutions and Non-Institutions held 54.79% and 16.00% respectively.
Cipla has launched Yurpeak (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) - two of the country’s most pressing health challenges. The company has the rights to distribute and promote Yurpeak - the second brand of Lilly’s tirzepatide in India, after Lilly received DCGI approval.
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of Type 2 diabetes and Chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. Yurpeak will be available on prescription in the KwikPen device format in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, allowing for precise, convenient, and patient-friendly dosing.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
